Biological markers in non-small cell lung cancer. Retrospective study of 10 year follow-up after surgery

Journal of Cardiovascular Surgery

Volumn 43, Issue 4, 2002, Pages 545-548

  Carbognani, P ^a   Tincani, G ^a   Crafa, P ^a   Sansebastiano, G ^a   Pazzini, L ^a   Zoni, R ^a   Bobbio, A ^a   Rusca, M ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Carcinoma, non small cell lung, diagnosis; Carcinoma, non small cell lung, immunology; Lung neoplasms; Survival

Indexed keywords

AVIDIN; BIOLOGICAL MARKER; BIOTIN; CD31 ANTIGEN; CD34 ANTIGEN; KI 67 ANTIGEN; PEROXIDASE; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CELL CYCLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE EXPRESSION; GROWTH REGULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE C ERB; PROGNOSIS; REGRESSION ANALYSIS; RELIABILITY; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADULT; AGED; ANTIGENS, CD31; ANTIGENS, CD34; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036696458     PISSN: 00219509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. D'Amico TA, Massey M, Herndon JE II, Moore MH, Harpole DH. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of 10 molecular markers. J Thorac Cardiovasc Surg 1999;117:736-43.
2. Harpole DH, Richards WG, Herndon JE II, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996;61:470-6.
3. 67Ki growth fraction. Cancer 1997;80:1034-45.
4. Yano T, Tanikawa S, Fujie T, Masutani M, Horie T. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer 2000;36:601-9.
5. 67Ki in lung carcinoma. Cancer 1994;74:2468-75.
6. Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993;103:449-56S.
7. Matsuyama K, Chiba Y, Sasaki M, Tanaka H, Muraoka R, Tanigawa N. Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer. Ann Thorac Surg 1998;65:1405-9.
8. Mountain CF. A new international stagin system for lung cancer. Chest 1986;89:225-31S.
9. Hsu SM, Raine L, Fanger H. Use of Avidin-Biotin Complex (ABC) in immunoperoxidase tecniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Citochem 1981;29:577-80.
10. D'Amico TA, Aloia TA, Moore MH, Herndon JE II, Brooks KR, Lau CL et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 2000;69: 882-6.
11. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997;15:2858-65.
12. Fong KM, Yoshitaka S, Minna JD. Molecular pathogenesis of lung cancer. J Thorac Cardiovasc Surg 1999;118:1136-52.
13. Kwiatkowski DJ, Harpole DH, Godleski J, Herndon JE II, Shieh DB, Richards W et al. Molecular pathologic substaging in 244 stage I non small cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-77.
14. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N et al. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995;13(B):1893-903.